FR05C0027I2 - - Google Patents

Info

Publication number
FR05C0027I2
FR05C0027I2 FR05C0027C FR05C0027C FR05C0027I2 FR 05C0027 I2 FR05C0027 I2 FR 05C0027I2 FR 05C0027 C FR05C0027 C FR 05C0027C FR 05C0027 C FR05C0027 C FR 05C0027C FR 05C0027 I2 FR05C0027 I2 FR 05C0027I2
Authority
FR
France
Prior art keywords
conopeptide
omega
medicament
manufacture
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR05C0027C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of FR05C0027I1 publication Critical patent/FR05C0027I1/fr
Application granted granted Critical
Publication of FR05C0027I2 publication Critical patent/FR05C0027I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Saccharide Compounds (AREA)
FR05C0027C 1995-06-27 2005-06-23 Active FR05C0027I2 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia
PCT/US1996/011041 WO1997001351A1 (en) 1995-06-27 1996-06-26 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Publications (2)

Publication Number Publication Date
FR05C0027I1 FR05C0027I1 (zh) 2005-08-12
FR05C0027I2 true FR05C0027I2 (zh) 2006-12-29

Family

ID=27052304

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0027C Active FR05C0027I2 (zh) 1995-06-27 2005-06-23

Country Status (14)

Country Link
EP (2) EP1336409B1 (zh)
JP (1) JP2838073B2 (zh)
AT (2) ATE359086T1 (zh)
AU (1) AU695166B2 (zh)
CA (1) CA2224795C (zh)
DE (3) DE69627153T2 (zh)
DK (2) DK1336409T3 (zh)
ES (2) ES2194998T3 (zh)
FR (1) FR05C0027I2 (zh)
HK (1) HK1058146A1 (zh)
LU (1) LU91181I2 (zh)
NL (1) NL300201I2 (zh)
PT (2) PT1336409E (zh)
WO (1) WO1997001351A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
EP1054896A1 (en) * 1998-02-20 2000-11-29 Zeneca Limited ANALGESIC PEPTIDES FROM VENOM OF $i(GRAMMOSTOLA SPATULATA) AND USE THEREOF
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP1578787B1 (en) 2002-12-02 2012-11-14 Xenome Ltd Novel chi-conotoxin peptides (-ii)
EP1572725B1 (en) 2002-12-02 2012-02-29 Xenome Ltd Chi-conotoxin peptides having a n-terminal pyroglutamic acid
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1594517B1 (en) 2003-01-28 2007-06-20 Microbia, Inc. Compositions for the treatment of gastrointestinal disorders
JP2007507538A (ja) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
WO2008054171A1 (en) * 2006-11-04 2008-05-08 Anygen Co., Ltd. Omega conotoxins
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20150336892A1 (en) 2012-08-21 2015-11-26 Ardelyx, Inc Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3552630A1 (en) 2013-04-12 2019-10-16 Ardelyx, Inc. Nhe3-binding compounds for inhibiting phosphate transport
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
JP2838073B2 (ja) 1998-12-16
ES2194998T3 (es) 2003-12-01
EP1336409B1 (en) 2007-04-11
EP1336409A1 (en) 2003-08-20
DE69637021T2 (de) 2008-01-10
ES2283671T3 (es) 2007-11-01
NL300201I2 (nl) 2006-02-01
HK1058146A1 (en) 2004-05-07
ATE235914T1 (de) 2003-04-15
ATE359086T1 (de) 2007-05-15
FR05C0027I1 (zh) 2005-08-12
AU695166B2 (en) 1998-08-06
AU6400296A (en) 1997-01-30
PT1336409E (pt) 2007-06-29
CA2224795A1 (en) 1997-01-16
NL300201I1 (nl) 2005-09-01
DE122005000043I1 (de) 2006-06-29
WO1997001351A1 (en) 1997-01-16
DK0835126T3 (da) 2003-07-14
EP0835126A1 (en) 1998-04-15
DE122005000043I2 (de) 2006-08-03
DK1336409T3 (da) 2007-08-13
JPH09104634A (ja) 1997-04-22
DE69627153T2 (de) 2003-12-04
PT835126E (pt) 2003-07-31
DE69637021D1 (de) 2007-05-24
CA2224795C (en) 2001-04-03
DE69627153D1 (de) 2003-05-08
LU91181I2 (fr) 2005-09-06
EP0835126B1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
FR05C0027I2 (zh)
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
IL123601A0 (en) Use of epinastine for the treatment of pain
IL121170A0 (en) Compositions for the treatment of dermatological disorders
GB2298440B (en) Well treatment
AU7545594A (en) Implantable device for the treatment of aedemas
ZA9610139B (en) Treatment of the cns effects of hiv
GB9512290D0 (en) Uses of polyhexanide
AU6328696A (en) Treatment of hemoglobinopathies
EP0668527A3 (en) Manufacture of a frictionless liquid crystal display device.
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU3105095A (en) Device for ensuring that medication is taken at the correct time
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
GB9303157D0 (en) Treatment of a group of related disorders
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AP9200355A0 (en) "Therapeutic agent"
HU9502623D0 (en) Use of substituted alkyl-nitrates for the treatment of pathologically increased intraocular pressure
GB9518887D0 (en) Treatment of muscular disorders
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
ZA947912B (en) Treatment of medical disorders associated with free radical formation
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
AU5419894A (en) Dental treatment aid
EP0622079A3 (en) Gelatinase A for the treatment of Alzheimer's disease.
AU5397994A (en) Treatment of skin disorders